MapLight Therapeutics (MPLT) news
Recent news
MapLight Therapeutics reports $150M placement financing
MapLight Therapeutics, a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system (CNS) disorders, has announced a $150 million placement financing as of August 13, 2026. This financing follows a significant $372.5 million Series D round in July 2025,…
AInvest Wire · Aug 13, 2026Morgan Stanley cuts MapLight Therapeutics Inc to equal weight from overweight; cuts target price to $21 from $34
AInvest Wire · Jul 28, 2026MapLight Therapeutics Inc: BMO cuts target price to $20 from $46
MapLight Therapeutics Inc. (NASDAQ:MPLT) has seen recent adjustments to analyst price targets following mixed clinical trial data. BMO Capital recently cut its target price for the stock to $20 from $46, citing updated expectations for the company’s pipeline. This follows a broader trend of…
AInvest Wire · Jul 28, 2026MapLight Therapeutics, Inc.: H.C. Wainwright cuts target price to $26 from $45
AInvest Wire · Jul 28, 2026MapLight Therapeutics Inc: Canaccord Genuity cuts target price to $24 from $43
AInvest Wire · Jul 28, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.